Doxorubicin, DNA torsion, and chromatin dynamics

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 1, 2014, Pages 84-89

  Yang, Fan ^a   Teves, Sheila S ^a   Kemp, Christopher J ^a   Henikoff, Steven ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Anthracycline; Cancer; Chemotherapy; Chromatin dynamics; DNA torsion; Doxorubicin

Indexed keywords

CERAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; VALPROIC ACID; VOSAROXIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL KILLING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN CONDENSATION; CHROMATIN STRUCTURE; DNA ADDUCT; DNA DAMAGE; DNA DENATURATION; DNA DRUG COMPLEX; DNA STRUCTURE; DNA TORSION; DRUG POTENTIATION; DRUG STRUCTURE; HEART FAILURE; HUMAN; INTERCALATION COMPLEX; LYMPHOMA; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION;

ANTHRACYCLINE; CANCER; CHEMOTHERAPY; CHROMATIN DYNAMICS; DNA TORSION; DOXORUBICIN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHROMATIN; DNA; DOXORUBICIN; HUMANS; NUCLEOSOMES; OXIDATIVE STRESS;

EID: 84891592249     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.12.002     Document Type: Review

References (79)

1. Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 1969, 11:1101-1110.
2. Di Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 1969, 53:33-37.
3. Thorn C.F., Oshiro C., Marsh S., Hernandez-Boussard T., McLeod H., Klein T.E., Altman R.B. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet. Genomics 2011, 21:440-446.
4. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
5. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
6. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 2001, 93:347-357.
7. Dixon J.R., Selvaraj S., Yue F., Kim A., Li Y., Shen Y., Hu M., Liu J.S., Ren B. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 2012, 485:376-380.
8. Bancaud A., Conde e Silva N., Barbi M., Wagner G., Allemand J.F., Mozziconacci J., Lavelle C., Croquette V., Victor J.M., Prunell A., Viovy J.L. Structural plasticity of single chromatin fibers revealed by torsional manipulation. Nat. Struct. Mol. Biol. 2006, 13:444-450.
9. Bancaud A., Wagner G., Conde E.S.N., Lavelle C., Wong H., Mozziconacci J., Barbi M., Sivolob A., Le Cam E., Mouawad L., Viovy J.L., Victor J.M., Prunell A. Nucleosome chiral transition under positive torsional stress in single chromatin fibers. Mol. Cell 2007, 27:135-147.
10. Pang B., Qiao X., Janssen L., Velds A., Groothuis T., Kerkhoven R., Nieuwland M., Ovaa H., Rottenberg S., van Tellingen O., Janssen J., Huijgens P., Zwart W., Neefjes J. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun. 2013, 4:1908.
11. Yang F., Kemp C.J., Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Curr. Biol. 2013, 23:782-787.
12. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17:421-433.
13. Carpenter A.J., Porter A.C. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol. Biol. Cell 2004, 15:5700-5711.
14. Wu C.C., Li T.K., Farh L., Lin L.Y., Lin T.S., Yu Y.J., Yen T.J., Chiang C.W., Chan N.L. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 2011, 333:459-462.
15. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9:338-350.
16. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9053-9058.
17. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006, 66:4863-4871.
18. Sorensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence, uncoupling the DNA binding, cleavage and religation events. J. Mol. Biol. 1992, 228:778-786.
19. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18:1639-1642.
20. Vavrova A., Jansova H., Mackova E., Machacek M., Haskova P., Tichotova L., Sterba M., Simunek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One 2013, 8:e76676.
21. Chaires J.B., Herrera J.E., Waring M.J. Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry 1990, 29:6145-6153.
22. Chaires J.B., Fox K.R., Herrera J.E., Britt M., Waring M.J. Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry 1987, 26:8227-8236.
23. Chen K.S., Gresh N., Pullman B. A theoretical investigation on the sequence selective binding of adriamycin to double-stranded polynucleotides. Nucleic Acids Res. 1986, 14:2251-2267.
24. Forrest R.A., Swift L.P., Rephaeli A., Nudelman A., Kimura K., Phillips D.R., Cutts S.M. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem. Pharmacol. 2012, 83:1602-1612.
25. Coldwell K.E., Cutts S.M., Ognibene T.J., Henderson P.T., Phillips D.R. Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res. 2008, 36:e100.
26. Taatjes D.J., Gaudiano G., Resing K., Koch T.H. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 1996, 39:4135-4138.
27. Taatjes D.J., Gaudiano G., Resing K., Koch T.H. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 1997, 40:1276-1286.
28. Kato S., Burke P.J., Koch T.H., Bierbaum V.M. Formaldehyde in human cancer cells: detection by preconcentration-chemical ionization mass spectrometry. Anal. Chem. 2001, 73:2992-2997.
29. Kato S., Burke P.J., Fenick D.J., Taatjes D.J., Bierbaum V.M., Koch T.H. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs. Chem. Res. Toxicol. 2000, 13:509-516.
30. Cutts S.M., Rephaeli A., Nudelman A., Hmelnitsky I., Phillips D.R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001, 61:8194-8202.
31. Cutts S.M., Nudelman A., Pillay V., Spencer D.M., Levovich I., Rephaeli A., Phillips D.R. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. Oncol. Res. 2005, 15:199-213.
32. Engel D., Nudelman A., Levovich I., Gruss-Fischer T., Entin-Meer M., Phillips D.R., Cutts S.M., Rephaeli A. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J. Cancer Res. Clin. Oncol. 2006, 132:673-683.
33. Rephaeli A., Waks-Yona S., Nudelman A., Tarasenko I., Tarasenko N., Phillips D.R., Cutts S.M., Kessler-Icekson G. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. Br. J. Cancer 2007, 96:1667-1674.
34. Berlin V., Haseltine W.A. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J. Biol. Chem. 1981, 256:4747-4756.
35. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 1998, 25:10-14.
36. Doroshow J.H., Synold T.W., Somlo G., Akman S.A., Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 2001, 97:2839-2845.
37. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Heide R.V. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1273-H1280.
38. Gajewski E., Gaur S., Akman S.A., Matsumoto L., van Balgooy J.N., Doroshow J.H. Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem. Pharmacol. 2007, 73:1947-1956.
39. De Beer E.L., Bottone A.E., Voest E.E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur. J. Pharmacol. 2001, 415:1-11.
40. Strigun A., Wahrheit J., Niklas J., Heinzle E., Noor F. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol. Sci. 2012, 125:595-606.
41. Rotili D., Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer 2011, 2:663-679.
42. Kirkland J.B. Niacin status impacts chromatin structure. J. Nutr. 2009, 139:2397-2401.
43. McBrian M.A., Behbahan I.S., Ferrari R., Su T., Huang T.W., Li K., Hong C.S., Christofk H.R., Vogelauer M., Seligson D.B., Kurdistani S.K. Histone acetylation regulates intracellular pH. Mol. Cell 2013, 49:310-321.
44. Kawase M., Watanabe M., Kondo T., Yabu T., Taguchi Y., Umehara H., Uchiyama T., Mizuno K., Okazaki T. Increase of ceramide in adriamycin-induced HL-60 cell apoptosis: detection by a novel anti-ceramide antibody. Biochim. Biophys. Acta 2002, 1584:104-114.
45. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., Cabot M.C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 1999, 86:300-311.
46. Delpy E., Hatem S.N., Andrieu N., de Vaumas C., Henaff M., Rucker-Martin C., Jaffrezou J.P., Laurent G., Levade T., Mercadier J.J. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc. Res. 1999, 43:398-407.
47. Chen Q., Denard B., Huang H., Ye J. Epigenetic silencing of antiviral genes renders clones of Huh-7 cells permissive for hepatitis C virus replication. J. Virol. 2013, 87:659-665.
48. Ji C., Yang B., Yang Y.L., He S.H., Miao D.S., He L., Bi Z.G. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29:6557-6568.
49. Uchida Y., Itoh M., Taguchi Y., Yamaoka S., Umehara H., Ichikawa S., Hirabayashi Y., Holleran W.M., Okazaki T. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res. 2004, 64:6271-6279.
50. Liu Y.Y., Yu J.Y., Yin D., Patwardhan G.A., Gupta V., Hirabayashi Y., Holleran W.M., Giuliano A.E., Jazwinski S.M., Gouaze-Andersson V., Consoli D.P., Cabot M.C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008, 22:2541-2551.
51. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15:719-730.
52. Liu Y.Y., Patwardhan G.A., Bhinge K., Gupta V., Gu X., Jazwinski S.M. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res. 2011, 71:2276-2285.
53. Denard B., Lee C., Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. Elife 2012, 1:e00090.
54. Comings D.E., Drets M.E. Mechanisms of chromosome banding. IX. Are variations in DNA base composition adequate to account for quinacrine, Hoechst 33258 and daunomycin banding?. Chromosoma 1976, 56:199-211.
55. Liu L.F., Wang J.C. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7024-7027.
56. Wu H.Y., Shyy S.H., Wang J.C., Liu L.F. Transcription generates positively and negatively supercoiled domains in the template. Cell 1988, 53:433-440.
57. Havas K., Flaus A., Phelan M., Kingston R., Wade P.A., Lilley D.M., Owen-Hughes T. Generation of superhelical torsion by ATP-dependent chromatin remodeling activities. Cell 2000, 103:1133-1142.
58. Thoma N.H., Czyzewski B.K., Alexeev A.A., Mazin A.V., Kowalczykowski S.C., Pavletich N.P. Structure of the SWI2/SNF2 chromatin-remodeling domain of eukaryotic Rad54. Nat. Struct. Mol. Biol. 2005, 12:350-356.
59. Gartenberg M.R., Wang J.C. Positive supercoiling of DNA greatly diminishes mRNA synthesis in yeast. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11461-11465.
60. Joshi R.S., Pina B., Roca J. Topoisomerase II is required for the production of long Pol II gene transcripts in yeast. Nucleic Acids Res. 2012, 40:7907-7915.
61. Salerno D., Brogioli D., Cassina V., Turchi D., Beretta G.L., Seruggia D., Ziano R., Zunino F., Mantegazza F. Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs. Nucleic Acids Res. 2010, 38:7089-7099.
62. Gupta P., Zlatanova J., Tomschik M. Nucleosome assembly depends on the torsion in the DNA molecule: a magnetic tweezers study. Biophys. J. 2009, 97:3150-3157.
63. Hizume K., Yoshimura S.H., Takeyasu K. Atomic force microscopy demonstrates a critical role of DNA superhelicity in nucleosome dynamics. Cell Biochem. Biophys. 2004, 40:249-261.
64. Clark D.J., Felsenfeld G. Formation of nucleosomes on positively supercoiled DNA. EMBO J. 1991, 10:387-395.
65. Teves S.S., Deal R.B., Henikoff S. Measuring genome-wide nucleosome turnover using CATCH-IT. Methods Enzymol. 2012, 513:169-184.
66. Deal R.B., Henikoff J.G., Henikoff S. Genome-wide kinetics of nucleosome turnover determined by metabolic labeling of histones. Science 2010, 328:1161-1164.
67. Jiang H., Reinhardt H.C., Bartkova J., Tommiska J., Blomqvist C., Nevanlinna H., Bartek J., Yaffe M.B., Hemann M.T. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009, 23:1895-1909.
68. Jackson J.G., Pant V., Li Q., Chang L.L., Quintas-Cardama A., Garza D., Tavana O., Yang P., Manshouri T., Li Y., El-Naggar A.K., Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21:793-806.
69. Lee M.S., Garrard W.T. Transcription-induced nucleosome 'splitting': an underlying structure for DNase I sensitive chromatin. EMBO J. 1991, 10:607-615.
70. Teves S.S., Henikoff S. Transcription-generated torsional stress destabilizes nucleosomes. Nat. Struct. Mol. Biol. 2013.
71. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 2009, 78:273-304.
72. Lehmann M., Vilar Kde S., Franco A., Reguly M.L., Rodrigues de Andrade H.H. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila somatic mutation and recombination test. Environ. Mol. Mutagen. 2004, 43:250-257.
73. Hawtin R.E., Stockett D.E., Byl J.A., McDowell R.S., Nguyen T., Arkin M.R., Conroy A., Yang W., Osheroff N., Fox J.A. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One 2010, 5:e10186.
74. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., Munster P.N. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther. 2005, 4:1993-2000.
75. Catalano M.G., Fortunati N., Pugliese M., Poli R., Bosco O., Mastrocola R., Aragno M., Boccuzzi G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 2006, 191:465-472.
76. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., Munster P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005, 65:3815-3822.
77. Cutts S.M., Nudelman A., Rephaeli A., Phillips D.R. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005, 57:73-81.
78. Wu S., Ko Y.S., Teng M.S., Ko Y.L., Hsu L.A., Hsueh C., Chou Y.Y., Liew C.C., Lee Y.S. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J. Mol. Cell. Cardiol. 2002, 34:1595-1607.
79. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 2004, 279:25535-25543.